ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0999

Clinical and Biological Features of VEXAS Syndrome in Women: Study of 9 French Cases Compared with 263 Men

Rim Bourguiba1, Valentin Lacombe2, Vincent Jachiet3, Thibault Comont4, Joris Galland5, Mael Heiblig6, Alexandre Nguyen7, Achille Aouba8, Xavier Boulu9, Alexandre Curie10, Pierre Sujobert11, Pierre Hirsch12, Olivier Kosmider13, Arsene Mekinian14 and Sophie Georgin-lavialle15, and French VEXAS study group, 1Hopital des Forces de sécurité de l'interieur, La Marsa, Tunisia, 2Angers University Hospital, Angers, France, 3Service de Médecine intene, Hopital Saint-Antoine, Paris France, Paris, France, 44 Service de médecine interne, Hopital Toulouse, France, Toulouse, France, 5Service de médecine interne, Centre hospitalier de Bourg- En-Bresse, France, Bourg en Bresse, France, 6Service de médecine interne, Centre Hospitalier Lyon Sud, Lyon, France, 7Service de médecine interne, CHU Cean, France, Cean, France, 8Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, 98 Service de médecine interne, CHU Amiens Picardie, France, Amiens, France, 10Service de médecine interne, CH Eure Seine, France, Eure seine, France, 11Service d'hématologie, Centre Hospitalier Lyon Sud, France, Lyon, Tunisia, 12Hopital Saint-Antoine, Paris, France, Paris, France, 13Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France, Paris, France, 14Saint Antoine University Hospital, Paris, France, 15Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: VEXAS syndrome is an autoinflammatory disease associated with somatic mutations in the UBA1 gene, which is located on the X chromosome, which explains the male preponderance of the disease [1].  Several case reports of females  with VEXAS syndrome have been published.

Our aim was to describe a series of female VEXAS from the French VEXAS cohort and to compare the clinical, biological and genetic characteristics of the disease between men and women.

Methods: A French national multicenter retrospective study was conducted between November 2020 and September 2023. All cases of VEXAS syndrome confirmed by the presence of a UBA1 mutation were included.

 

Results: The French cohort included 263 patients with VEXAS syndrome, 9 of whom (3%) were women with a mean age of 72.6 (± 10.4) years, which was not significantly different from men (p=0.56).

Clinically, the VEXAS syndrome in these 9 women was characterized by the presence of fever (n=8), altered general condition (n=5), neutrophilic dermatosis (n=3), chondritis (n=4), pulmonary infiltrate (n=3) and thromboembolic events (n=1). Comparison with the cohort of 263 men showed no statistically significant difference except for diarrhea (8/263 men  vs 1/9 women, p=0.05) and aortitis (7/263 men vs 1/9 women, p=0.04), which were observed more common in women.

In the female group, the median CRP was 56 mg/l [22-128].  Myelograms were performed in 8 patients; myeloid vacuoles were reported in five patients. The main features of the myelogram were MDS with a single lineage dysplasia (n=2), MDS with ring siberoblast (n=2), MDS with isolated del(5q) (n=1). Bone marrow karyotype showed X monosomy in 7 patients. Anemia was more profound in females: the mean hemoglobin level at diagnosis was 8.96 g/dl (± 0.96) versus 11.18 g/dl (± 10.1) in males (p=0.02). There was no difference in median corpuscular volume (103.45 (± 8.6) fl in women versus 101.46 (± 8.1) fl in men, p=0.44). 

UBA1 mutations in women were: p.M14V (n=4), p.M41L (n=2), p.M41T (n=2), other mutation in UBA1 c.T122C (20% detected with new generation sequencing) in one patient. Two additional mutations were identified by next-generation sequencing: ASXL1 (n=2) and U2AF1 (n=1).
During follow-up period, only one patient died in the female group.

Conclusion: This is the largest series of women diagnosed with VEXAS syndrome and supports what has been reported previously that VEXAS syndrome can affect women, although less frequently. The main clinical and laboratory features were similar to those reported in the first French series of patients with VEXAS [1]. Anemia was more profound in women than in men. In the presence of a suggestive clinical picture associated with macrocytic anemia and a biological inflammatory syndrome, sequencing of the UBA1 gene should be considered in both females and males especially in those with known Turner syndrome or X monosomia.


Disclosures: R. Bourguiba: None; V. Lacombe: None; V. Jachiet: None; T. Comont: None; J. Galland: None; M. Heiblig: None; A. Nguyen: None; A. Aouba: None; X. Boulu: None; A. Curie: None; P. Sujobert: None; P. Hirsch: None; O. Kosmider: None; A. Mekinian: None; S. Georgin-lavialle: None.

To cite this abstract in AMA style:

Bourguiba R, Lacombe V, Jachiet V, Comont T, Galland J, Heiblig M, Nguyen A, Aouba A, Boulu X, Curie A, Sujobert P, Hirsch P, Kosmider O, Mekinian A, Georgin-lavialle S. Clinical and Biological Features of VEXAS Syndrome in Women: Study of 9 French Cases Compared with 263 Men [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinical-and-biological-features-of-vexas-syndrome-in-women-study-of-9-french-cases-compared-with-263-men/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-biological-features-of-vexas-syndrome-in-women-study-of-9-french-cases-compared-with-263-men/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology